Skip to main content
. Author manuscript; available in PMC: 2015 Jan 2.
Published in final edited form as: Cell Stem Cell. 2014 Jan 2;14(1):121–130. doi: 10.1016/j.stem.2013.11.014

Figure 1.

Figure 1

Hu-mice can mount robust immune rejection of hESC-derived allografts. (A) Representative FACS analysis of spleen, peripheral blood mononuclear cells (PBMC) and transplanted human thymus derived from Hu-mice. Single cell suspension was stained for the markers of human T cells (CD3, CD4, and CD8) and B cells (CD19). N>10. Single cell suspension derived from the spleen of NSG mice was used as a negative control. (B) Sections of spleens from NSG and Hu-mice were stained with hematoxylin and eosin, or with antibodies against human CD3, CD4, CD8, and human nuclei to show the repopulation of human T cells in spleen. Nuclei were counterstained with DAPI. Scale bar, 100 μm. Representative images are shown. N=4 for NSG group, N>20 for Hu-mice group. (C) NSG and Hu-mice were subcutaneously implanted with allogeneic Hues 3 and Hues 8 hESCs around the hindlegs. Six-to-eight weeks after implantation, teratomas were harvested, sectioned and stained with anti-human CD4 and CD8 antibodies. (D) Extensive necrosis was detected in the teratomas formed by allogeneic Hues 3 and Hues 8 hESCs in Hu-mice, as revealed by hematoxylin and eosin staining. N=4 for Hues 3/Hu-mice group, N=6 for Hues 8/Hu-mice group, N>10 for Hues 3/NSG group, N>10 for Hues 8/NSG group. See also table S1.